Advertisement
CLDX vs XNCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and XNCR is a Hold.
CLDX's Indicator enters downward trend
The Aroon Indicator for CLDX entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 240 similar instances where the Aroon Indicator formed such a pattern. In 200 of the 240 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 24 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 59 cases where CLDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CLDX just turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 206 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.215) is normal, around the industry mean (3.043). P/E Ratio (-6.724) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for XNCR turns positive, indicating new upward trend
XNCR saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 58 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 189 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
XNCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
XNCR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XNCR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.720) is normal, around the industry mean (3.043). P/E Ratio (-11.657) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLDX | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 63 | 35 | |
P/E GROWTH RATING 1..100 | 23 | 81 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (19) in the Biotechnology industry is significantly better than the same rating for CLDX (99). This means that XNCR’s stock grew significantly faster than CLDX’s over the last 12 months.
XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that XNCR’s stock grew similarly to CLDX’s over the last 12 months.
XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as CLDX (98). This means that XNCR’s stock grew similarly to CLDX’s over the last 12 months.
XNCR's Price Growth Rating (35) in the Biotechnology industry is in the same range as CLDX (63). This means that XNCR’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's P/E Growth Rating (23) in the Biotechnology industry is somewhat better than the same rating for XNCR (81). This means that CLDX’s stock grew somewhat faster than XNCR’s over the last 12 months.
| CLDX | XNCR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 71% |
| Momentum ODDS (%) | N/A | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 73% |
| Advances ODDS (%) | 5 days ago 77% | 3 days ago 74% |
| Declines ODDS (%) | 3 days ago 78% | 11 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLDX’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
- CLDX’s FA Score: 1 green, 4 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLDX’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).
- CLDX’s TA Score: 5 bullish, 2 bearish.
- XNCR’s TA Score: 4 bullish, 5 bearish.
Price Growth
CLDX (@Biotechnology) experienced а +6.25% price change this week, while XNCR (@Biotechnology) price change was +10.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
CLDX is expected to report earnings on Nov 09, 2026.
XNCR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HYTR | 20.76 | 0.01 | +0.02% |
| Counterpoint High Yield Trend ETF (HYTR) | |||
| NYNY | 26.72 | N/A | N/A |
| Corgi NYC Based ETF (NYNY) | |||
| KEMQ | 22.95 | -0.05 | -0.21% |
| KraneShares Public-Private Emerging Markets Internet and Technology ETF (KEMQ) | |||
| VCEB | 60.18 | -0.23 | -0.38% |
| Vanguard ESG U.S. Corporate Bond ETF (VCEB) | |||
| GLIN | 43.63 | -1.07 | -2.40% |
| VanEck India Growth Leaders ETF (GLIN) | |||